Clinical Trial Update: Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cryoablation combined with tislelizumab and lenvatinib in melanoma with liver metastasis is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cryoablation
• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Melanoma | Phase 2 | Status: UNKNOWN